A detailed history of Sumitomo Mitsui Ds Asset Management Company, LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Sumitomo Mitsui Ds Asset Management Company, LTD holds 261,388 shares of BMY stock, worth $15.4 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
261,388
Previous 254,048 2.89%
Holding current value
$15.4 Million
Previous $10.6 Million 28.21%
% of portfolio
0.15%
Previous 0.13%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$39.66 - $51.75 $291,104 - $379,845
7,340 Added 2.89%
261,388 $13.5 Million
Q2 2024

Jul 30, 2024

BUY
$40.25 - $52.99 $23,626 - $31,105
587 Added 0.23%
254,048 $10.6 Million
Q1 2024

May 02, 2024

BUY
$47.98 - $54.4 $1.15 Million - $1.31 Million
24,049 Added 10.48%
253,461 $13.7 Million
Q4 2023

Feb 01, 2024

BUY
$48.48 - $57.85 $5,284 - $6,305
109 Added 0.05%
229,412 $11.8 Million
Q3 2023

Oct 30, 2023

BUY
$57.89 - $64.73 $146,866 - $164,220
2,537 Added 1.12%
229,303 $13.3 Million
Q2 2023

Aug 04, 2023

BUY
$63.71 - $70.74 $2.82 Million - $3.13 Million
44,213 Added 24.22%
226,766 $14.5 Million
Q1 2023

May 02, 2023

BUY
$65.71 - $74.53 $511,420 - $580,066
7,783 Added 4.45%
182,553 $12.7 Million
Q4 2022

Jan 26, 2023

BUY
$68.48 - $81.09 $557,153 - $659,748
8,136 Added 4.88%
174,770 $0
Q3 2022

Oct 19, 2022

BUY
$0.13 - $76.84 $1,013 - $598,890
7,794 Added 4.91%
166,634 $11.8 Million
Q2 2022

Jul 13, 2022

BUY
$72.62 - $79.98 $903,320 - $994,871
12,439 Added 8.5%
158,840 $12.2 Million
Q1 2022

Apr 19, 2022

SELL
$61.48 - $73.72 $185,977 - $223,003
-3,025 Reduced 2.02%
146,401 $10.7 Million
Q4 2021

Jan 20, 2022

BUY
$53.63 - $62.52 $261,821 - $305,222
4,882 Added 3.38%
149,426 $9.32 Million
Q3 2021

Oct 15, 2021

SELL
$59.17 - $69.31 $56,507 - $66,191
-955 Reduced 0.66%
144,544 $8.55 Million
Q2 2021

Jul 19, 2021

SELL
$61.91 - $67.42 $77,449 - $84,342
-1,251 Reduced 0.85%
145,499 $9.72 Million
Q1 2021

May 07, 2021

BUY
$59.34 - $66.74 $60,526 - $68,074
1,020 Added 0.7%
146,750 $9.26 Million
Q4 2020

Feb 02, 2021

SELL
$57.74 - $65.43 $152,202 - $172,473
-2,636 Reduced 1.78%
145,730 $9.04 Million
Q3 2020

Oct 29, 2020

BUY
$57.43 - $63.64 $254,931 - $282,497
4,439 Added 3.08%
148,366 $8.94 Million
Q2 2020

Aug 12, 2020

SELL
$54.82 - $64.09 $160,129 - $187,206
-2,921 Reduced 1.99%
143,927 $8.46 Million
Q1 2020

Apr 21, 2020

SELL
$46.4 - $67.43 $36,099 - $52,460
-778 Reduced 0.53%
146,848 $8.19 Million
Q4 2019

Jan 24, 2020

BUY
$49.21 - $64.19 $2.26 Million - $2.94 Million
45,831 Added 45.02%
147,626 $9.48 Million
Q3 2019

Oct 16, 2019

BUY
$42.77 - $50.71 $413,158 - $489,858
9,660 Added 10.48%
101,795 $5.16 Million
Q2 2019

Aug 13, 2019

SELL
$44.62 - $49.34 $1.02 Million - $1.13 Million
-22,803 Reduced 19.84%
92,135 $4.18 Million
Q1 2019

May 07, 2019

BUY
$45.12 - $53.8 $263,049 - $313,654
5,830 Added 5.34%
114,938 $5.48 Million
Q4 2018

Jan 25, 2019

SELL
$48.76 - $63.23 $248,968 - $322,852
-5,106 Reduced 4.47%
109,108 $5.67 Million
Q3 2018

Oct 15, 2018

SELL
$55.19 - $62.25 $44,759 - $50,484
-811 Reduced 0.71%
114,214 $7.09 Million
Q2 2018

Jul 31, 2018

BUY
$50.53 - $62.98 $53,966 - $67,262
1,068 Added 0.94%
115,025 $6.37 Million
Q1 2018

Apr 25, 2018

SELL
$59.92 - $68.98 $235,545 - $271,160
-3,931 Reduced 3.33%
113,957 $7.21 Million
Q4 2017

Jan 25, 2018

SELL
$59.94 - $65.35 $471,248 - $513,781
-7,862 Reduced 6.25%
117,888 $7.22 Million
Q3 2017

Oct 27, 2017

BUY
$55.23 - $63.74 $6.95 Million - $8.02 Million
125,750
125,750 $8.02 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Sumitomo Mitsui Ds Asset Management Company, LTD Portfolio

Follow Sumitomo Mitsui Ds Asset Management Company, LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Ds Asset Management Company, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Ds Asset Management Company, LTD with notifications on news.